AAGP® Research

See the promising research and results to date

In partnership with some of the world’s top researchers, ProtoKinetix has conducted more than a decade of laboratory testing throughout Europe and North America. Our proprietary anti-aging glycopeptide, AAGP®, has gone through a series of pre-clinical studies and is being evaluated in a clinical setting, and the results have been extremely promising. Learn about our research protocols and the potential we see for AAGP®.

Explore our research

Test cells icon

See how AAGP® protects human islets against tacrolimus-related injury

Test tubes flask icon

Review AAGP®’s cytoprotective capacity and safety for islet transplantation

Microscope image

Find out where are today and where we are heading next.

Test cells icon

See the cells lines we’ve examined to uncover AAGP®’s potential.  

Test tubes flask icon

Review the results of our AAGP® dose and toxicity studies.

Papers notebook icon

Learn how we’ve analyzed AAGP®’s concentration and potency.

Microscope image

Find out where are today and where we are heading next.

Dr. Kevin Gregory-Evans, lead macular researcher for ProtoKinetix, examines a specimen under a microscope.
A research assistant at The University of British Columbia takes a closer look at AAGP®-treated cells.
A vial containing an AAGP® solution is prepared for testing at The University of British Columbia.

What does the research show?

Cells protected by AAGP® were subjected to UVA, UVC, hydrogen peroxide, inflammatory (ILβ), time, temperature (-196°C, -80°C, -3°C, 3°C, 4°C, 15°C and 22°C) and low serum induced cell death at a pH of 5.3-10.5, in a laboratory setting. The average increase in cell survival credited to AAGP® in the face of these conditions was over 55%. This cannot be attributed to AAGP® increasing cell proliferation as it has been found that AAGP® has no effect on cell doubling times in either Hela or fibroblast cells.
In addition to protecting cell survival, AAGP® has also been shown to preserve cell functionality. This has been tested not only with stem cell markers and CD34+ functionality tests but also in vivo studies where AAGP®-treated transplanted islet cells were found to reduce blood glucose concentrations in diabetic mice by 40% by day 40 in comparison to islet cells which were transplanted into mice without first being exposed to AAGP®.
  • Untreated
  • Treated

Research partners

Since 2005, AAGP® has gone through international laboratory testing conducted by some of the top researchers in the world. See their scientific contributions.

Create a secure online account

Connect With Protokinetix

Contact the team at ProtoKinetix to learn more about AAGP®’s performance in research studies.

Picture of a molecule
Picture of a molecule